Terminated × Lymphoma, Large B-Cell, Diffuse × 1 year × Clear all Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 Terminated
5 enrolled 13 charts
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1 Terminated
3 enrolled
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
Phase 1 Terminated
18 enrolled
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
Phase 1 Terminated
84 enrolled
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Terminated
1 enrolled
Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma
Phase 2 Terminated
23 enrolled
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
Phase 2 Terminated
5 enrolled 11 charts
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Phase 1 Terminated
22 enrolled
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
Phase 2 Terminated
14 enrolled 15 charts
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase 1/2 Terminated
130 enrolled
ELiPSE-1
Phase 1 Terminated
28 enrolled
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
Phase 1 Terminated
15 enrolled
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1/2 Terminated
6 enrolled 17 charts
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
Phase 1 Terminated
139 enrolled
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
Phase 2 Terminated
37 enrolled
Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Phase 1 Terminated
1 enrolled
Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
Phase 2 Terminated
18 enrolled 14 charts
ALEXANDER
Phase 1/2 Terminated
52 enrolled 29 charts
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Phase 1 Terminated
55 enrolled
A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 1 Terminated
13 enrolled 10 charts
GLEAN-1
Phase 1 Terminated
34 enrolled
SWATCH
Phase 1/2 Terminated
54 enrolled
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Phase 2 Terminated
150 enrolled
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
Phase 2 Terminated
2 enrolled 6 charts
FIRCE-1
Phase 2 Terminated
101 enrolled